Troublesome Dyskinesia

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

The FDA has approved Vyalev, a continuous, subcutaneous 24-hour infusion, to address motor fluctuations in adults with advanced Parkinson's disease, according to the manufacturer.

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease, data from The Lancet Neurology show.

Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study.